Enter your search term above.

Research partnerships

LCRF is proud to partner with several patient advocacy groups to fund much needed research focusing on specific types of lung cancer.

ALK Positive

ALK Positive is committed to raising funds for research that will transform ALK-positive cancer into a chronic or curable condition for all patients living with this disease.

Together, LCRF and ALK Positive are funding three grants totaling $750,000 to advance high-impact research focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). 2022 Awardees are:

Jaime Schneider, MD, PhD
Massachusetts General Hospital

Álvaro Villalonga, PhD
Memorial Sloan-Kettering Cancer Center

EGFR Resisters

EGFR Resisters is a grassroots patient-driven community, dedicated exclusively to changing EGFR positive lung cancer into a manageable, chronic disease.

In 2021, LCRF and the EGFR Resisters partnered to fund Dr. Yang Tian, Icahn School of Medicine at Mt. Sinai, and her work on resistance to targeted therapy. Together, LCRF and EGFR Resisters funded three more impactful grants in 2022 in the area of EGFR lung cancer research.

2022 Awardees are:

Swarnali Acharyya, PhD Columbia University Medical Center

Luke Hoeppner, PhD University of Minnesota, Twin Cities

Jonathan Ostrem, MD, PhD University of California, San Francisco

KRAS Kickers

KRAS Kickers is a non-profit patient founded organization with a mission to connect people to current research, resources, and community to kick cancer’s KRAS. The group empowers patients, brings doctors and researchers with cutting-edge information together in an approachable virtual patient community.

Together, LCRF and KRAS Kickers funded a two-year grant in 2022 with the goal of improving outcomes for people with KRAS-mutant lung cancer. 2022 Awardee is:

Matthew Gumbleton, MD, PhD The University of Utah

MET Crusaders

MET Crusaders are a community of lung cancer patients, care givers, advocates, researchers, and physicians dedicated to helping patients with the MET alteration live normal lives.

Together, LCRF and MET Crusaders funded three projects in 2022 with the goal of improving outcomes for people with MET-mutant lung cancer.

2022 Awardees are:

Timothy Burns, MD, PhD University of Pittsburgh

Emiliano Cocco, PhD Miller School of Medicine of the University of Miami

Xiuning Le, MD, PhD University of Texas MD Anderson Cancer Center

Does your group have an idea for a project to further lung cancer research? Let’s talk! Email Natalie Reilly-Finch at nfinch@LCRF.org or use this form.